Minimally differentiated acute myeloid leukemia (FAB AML-M0): Prognostic factors and treatment effects on survival—A retrospective study of 42 adult cases

Gougounon, Alice; Abahssain, Halima; Rigollet, Lauren; Elhamri, Mohamed; Tigaud, Isabelle; Chelghoum, Youcef; Pleşa, Adriana; Dumontet, Charles; Michallet, Mauricette; Thomas, Xavier

doi:10.1016/j.leukres.2011.02.015

Cited by 8 publications

(6 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Among the various types of AML, AML-M0 is regarded as a relatively rare disorder with an incidence of 2-4% 13) . AML-M0 blasts exhibit large and agranular features, and frequently lack those of a specific cell lineage, precluding diagnosis on morphological grounds alone 2) .…”

Section: Discussionmentioning

confidence: 99%

Acute Undifferentiated Leukemia or Minimally Differentiated Acute Myeloid Leukemia: Further Emphasis on Molecular Analysis in Leukemia Diagnosis

Kakimoto

Otsubo

Hanawa

et al. 2016

Juntendo Medical Journal

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

Acute Undifferentiated Leukemia or Minimally Differentiated Acute Myeloid Leukemia: Further Emphasis on Molecular Analysis in Leukemia Diagnosis

Kakimoto

Otsubo

Hanawa

et al. 2016

Juntendo Medical Journal

View full text Add to dashboard Cite

“…Expression of CD34 and HLA-DR ranged from 83% to 100% M0 cases. CD117, a protein preferentially expressed on immature myeloid leukemia cells [23] , ranged from 50% to 80% in M0 cases [23][24][25][26] .…”

Section: Early Progenitors and Leukemia Stem Cellsmentioning

confidence: 99%

“…In clinical settings, inclusion of CD34, CD38, CD117, CD133, HLA-DR are not mandatory in the AML diagnosis panel [3] . The CD34+CD38-pattern of expression was not reported in many of the studies on M0 [10,[23][24][25][26][27]34,35] . CD34+CD38-cells were observed in all subtypes of AML analysed [33] .…”

Section: Introductionmentioning

confidence: 99%

Less Utilized Prognostic Markers in Acute Myeloid Leukemia

Abdullah

2016

International Journal of Hematology Research

View full text Add to dashboard Cite

Acute myeloid leukemia (AML) results from the over-proliferation of progenitor cells of the myeloid lineage in the bone marrow. It is a heterogeneous disease that is aggressive and difficult to treat. AML diagnosis is based on clinical as well as laboratory investigations. Risk stratification is important to assess risk of relapse. Current guidelines for risk stratification are dependent on identification of genetic aberrations particularly chromosomal translocations and gene mutations. Though these are observed in the majority of patients, the best treatment regimen remains elusive. AML blasts are assumed to have transformed from a normal counterpart and maintains many normal regulatory functions. Early features such as stem cell properties has long been proven to be linked to early relapse in AML. Leukaemia stem cells (LSC) are identified by high CD34 and negative CD38 expression. Aberrant expression of a third marker such as Thy-1/CD90 negativity, expression of CLL-1 and IL-3R (CD123), intermediate levels of aldehyde dehydrogenase and co-expression of common chromosomal translocation may be used to distinguish from normal hematopoietic stem cells. In vitro characteristics of AML blasts such as proliferation, survival or response to treatment are also able to predict patient response to therapy, replicative of its interaction with the microenvironment. These potential prognostic markers are well studied but are currently not considered in patient management.

show abstract

“…In addition, diagnostic distinction from AML by immunophenotype is often not clear-cut, as immature T-ALLs commonly express myeloid lineageassociated markers [14]. Conversely, the most phenotypically immature AML subgroup, M0-AML, is also biologically heterogeneous and expresses lymphoid-associated antigens such as CD7 or TdT in about 50% of cases [15]. Immature T-ALLs are frequently chemoresistant and require intensive treatment [10,14,16], while M0-AML cases have poor outcomes compared to other AML subgroups [17,18], so it is clinically important to consider whether improved classification of these cases might allow better therapeutic choices.…”

Section: Introductionmentioning

confidence: 99%

A transcriptomic continuum of differentiation arrest identifies myeloid interface acute leukemias with poor prognosis

et al. 2020

View full text Add to dashboard Cite

Classification of acute lymphoblastic and myeloid leukemias (ALL and AML) remains heavily based on phenotypic resemblance to normal hematopoietic precursors. This framework can provide diagnostic challenges for immunophenotypically heterogeneous immature leukemias, and ignores recent advances in understanding of developmental multipotency of diverse normal hematopoietic progenitor populations that are identified by transcriptional signatures. We performed transcriptional analyses of a large series of acute myeloid and lymphoid leukemias and detected significant overlap in gene expression between cases in different diagnostic categories. Bioinformatic classification of leukemias along a continuum of hematopoietic differentiation identified leukemias at the myeloid/T-lymphoid interface, which shared gene expression programs with a series of multi or oligopotent hematopoietic progenitor populations, including the most immature CD34+CD1a−CD7− subset of early thymic precursors. Within these interface acute leukemias (IALs), transcriptional resemblance to early lymphoid progenitor populations and biphenotypic leukemias was more evident in cases originally diagnosed as AML, rather than T-ALL. Further prognostic analyses revealed that expression of IAL transcriptional programs significantly correlated with poor outcome in independent AML patient cohorts. Our results suggest that traditional binary approaches to acute leukemia categorization are reductive, and that identification of IALs could allow better treatment allocation and evaluation of therapeutic options.

show abstract

Minimally differentiated acute myeloid leukemia (FAB AML-M0): Prognostic factors and treatment effects on survival—A retrospective study of 42 adult cases

Cited by 8 publications

References 22 publications

Acute Undifferentiated Leukemia or Minimally Differentiated Acute Myeloid Leukemia: Further Emphasis on Molecular Analysis in Leukemia Diagnosis

Acute Undifferentiated Leukemia or Minimally Differentiated Acute Myeloid Leukemia: Further Emphasis on Molecular Analysis in Leukemia Diagnosis

Less Utilized Prognostic Markers in Acute Myeloid Leukemia

A transcriptomic continuum of differentiation arrest identifies myeloid interface acute leukemias with poor prognosis

Contact Info

Product

Resources

About